Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation:outcomes and treatment effect across different levels of risk

Joyner, Campbell D, Peters, Ron J G, Afzal, Rizwan, Chrolavicius, Susan, Mehta, Shamir R, Fox, Keith A A, Granger, Christopher B, Franzosi, Maria Grazia, Flather, Marcus, Budaj, Andrzej, Bassand, Jean-Pierre and Yusuf, Salim (2009) Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation:outcomes and treatment effect across different levels of risk. American Heart Journal, 157 (3). pp. 502-8. ISSN 0002-8703

Full text not available from this repository. (Request a copy)

Abstract

The OASIS-5 (Organization to Assess Strategies in Ischemic Syndromes-5) trial demonstrated that fondaparinux was noninferior to enoxaparin while reducing the risk of bleeding by 50%. The objectives of our study were to assess the effects of fondaparinux compared to enoxaparin in patients stratified by their Global Registry of Acute Coronary Events (GRACE) score and to examine the ability of the GRACE score to predict bleeding in patients with acute coronary syndromes (ACS).

Item Type:	Article
Uncontrolled Keywords:	acute coronary syndrome,anticoagulants,enoxaparin,hemorrhage,humans,polysaccharides,prognosis,risk assessment,treatment outcome
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User:	Pure Connector
Date Deposited:	20 Jan 2014 16:14
Last Modified:	24 Oct 2022 05:36
URI:	https://ueaeprints.uea.ac.uk/id/eprint/46264
DOI:	10.1016/j.ahj.2008.10.028

Actions (login required)

View Item